Category: Infectious Diseases
-
Biocomposites gains wider antimicrobial approval in India
The company’s Stimulan Rapid Cure can now be mixed with more antibiotics and antifungals in India to combat surgical infections.
-
Cidara secures $339m from BARDA for non-vaccine flu therapy
Cidara Therapeutics wins BARDA backing to expand US manufacturing and clinical development of its long-acting, non-vaccine influenza therapeutic, CD388.
-
PACE adds £6 million in funding to combat superbugs
The funding is part of a broader £30 million investment from PACE, one of the UK’s largest public-private initiatives, to accelerate solutions for global AMR challenges.
-
BiomX’s phage therapy shows promise in tackling chronic infections in CF
New data underscores the potential of phage therapy as an alternative to antibiotics in the fight against resistant bacterial infections.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.